[시장보고서]암 화학요법 관련 오심 및 구토 치료제 시장 : 유형별, 약제 클래스별, 투여 경로별, 유통 채널별, 지역별

암 화학요법 관련 오심 및 구토 치료제 시장 : 유형별, 약제 클래스별, 투여 경로별, 유통 채널별, 지역별

Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Type, By Drug Class, By Route of Administration, By Distribution Channel, and By Region

상품코드 : 1741105

리서치사 : Coherent Market Insights

발행일 : 2025년 03월

페이지 정보 : 영문

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,676,000

Unprintable PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 7,000

￦ 10,385,000

PDF & Excel (Multi User License - Up to 7 Users)

PDF & Excel 보고서를 동일 기업 최대 7명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능하며, 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

US $ 10,000

￦ 14,837,000

PDF & Excel (Corporate User License)

PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

암 화학요법 관련 오심 및 구토 치료제 시장은 2025년에는 34억 3,100만 달러로 추정되고, 2032년에는 50억 5,760만 달러에 이를 것으로 예측되며, 2025년부터 2032년까지 연간 평균 성장률(CAGR)은 5.7%를 나타낼 것으로 전망됩니다.

보고 범위		보고서 세부정보
기준 연도	2024년	시장 규모(2025년)	34억 3,100만 달러
실적 데이터	2020-2024년	예측 기간	2025-2032년
예측 기간 : 2025-2032년 CAGR :	5.70%	가치 예측(2032년)	50억 5,760만 달러

암 환자의 치료는 오심과 구토(N&V)의 예방과 대조를 우선해야 합니다. 이것은 환자의 QOL을 현저하게 낮추고, 최대 80%의 환자에게 일어납니다. 오심과 구토(N&V)를 제어하는 신경 생리 시스템의 이해는 진행 중입니다.

구토 시 구심성 입력의 수렴을 포함한 복잡한 반응이 자극됩니다. 경전 전달 물질이 구심성 임펄스를 발합니다. 이 신경 전달 물질에는 세로토닌, 서브 스탠스 P, 도파민 등이 있습니다. N&V 증상을 초래하는 이러한 여러 경로의 상대적 중요성은 복잡합니다.

시장 역학

암 화학요법 관련 오심 및 구토 치료제는 구역과 구토를 예방하기 위해 화학요법을 받는 환자에게 투여됩니다. 화학요법을 받는 환자 증가는 예측 기간 동안 시장 성장을 가속할 것으로 전망됩니다. 예를 들어, 미국 질병 예방 관리 센터가 제공한 데이터에 따르면, 2022년 11월, 미국에서는 매년 100만명 이상의 암 환자가 외래 종양과 클리닉에서 화학요법이나 방사선요법을 받았습니다.

본 조사의 주요 특징

본 보고서에서는 세계의 암 화학요법 관련 오심 및 구토 치료제 시장을 상세하게 분석하고, 2024년을 기준연도로 한 예측기간 2025-2032년 시장 규모 및 CAGR을 제공합니다.
또, 다양한 부문에 걸친 잠재적인 수익 기회를 해명해, 이 시장의 매력적인 투자 제안 매트릭스에 대해서 해설했습니다.
또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시나 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 인사이트도 제공합니다.
세계의 암 화학요법 관련 오심 및 구토 치료제 시장에서 주요 기업을 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 실적, 전략 등의 파라미터에 근거하여 프로파일하고 있습니다.
본 보고서로부터의 인사이트에 의해 마케팅 담당자나 기업의 경영진은 향후 제품 발매, 유형 업그레이드, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시할 수 있습니다.
세계의 암 화학요법 관련 오심 및 구토 치료제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자에 대응하고 있습니다.
이해관계자는 세계의 암 화학요법 관련 오심 및 구토 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해, 의사 결정을 용이하게 할 수 있습니다.

도파민 수용체 길항제
메토클로프라미드
클로르프로마진
프로클로르페라진
할로페리돌
드로페리돌
기타
세로토닌(5-HT3) 수용체 길항제
온단세트론
그라니세트론
팔로노세트론
돌라세트론
기타
서브스탠스 P/NK-1 길항제
아프리피탄트
포사프리피탄트
네투피탄트
기타
코르티코스테로이드
덱사메타손
메틸프레드니솔론
기타

제7장 세계의 암 화학요법 관련 오심 및 구토 치료제 시장, 투여 경로별(2020-2032년)

경구
비경구
경피 패치

제8장 세계의 암 화학요법 관련 오심 및 구토 치료제 시장, 유통 채널별(2020-2032년)

병원 약국
소매 약국
온라인 약국

제9장 세계의 암 화학요법 관련 오심 및 구토 치료제 시장, 지역별(2020-2032년)

북미
라틴아메리카
유럽
아시아태평양
중동
아프리카

제10장 경쟁 구도

Eisai Co. Ltd.
Pharmanovia
Novartis AG
- Company Highlight
Merck & Co. Inc.
- Company Highlight
Helsinn Healthcare SA
Reddy's Laboratories Ltd.
Validus Pharmaceuticals LLC
LGM Pharma
Astellas Pharma Inc.
AdvaCare Pharma
Norgine
PV Pharma
Fresenius Kabi
Lupin
Hetero Healthcare Limited.
Sino Biopharmaceutical Limited
Glenmark Pharmaceuticals Ltd.
Otsuka Pharmaceutical Co. Ltd
OPKO Health, Inc.
Weefsel Pharma
Pfizer Inc.
Rosemont Pharmaceuticals Ltd.
Starton Therapeutics

제11장 섹션

조사 방법
출판사에 대해

KTH

영문 목차

영문목차

Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market is estimated to be valued at USD 3,431.0 Mn in 2025 and is expected to reach USD 5,057.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 3,431.0 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.70%	2032 Value Projection:	USD 5,057.6 Mn

Treatment for cancer patients must prioritize preventing and controlling nausea and vomiting (N&V). One of the most prevalent and upsetting acute adverse effects of chemotherapy-induced nausea and vomiting (N&V) is cancer treatment. It can significantly lower a patient's quality of life and happens in up to 80% of patients. The perceptual feeling of nausea is an unpleasant, wave-like sensation in the epigastrium and/or back of the throat that may lead to vomiting (emesis). Emesis, the violent evacuation of stomach, duodenal, or jejunal contents through the oral canal, is referred to as vomiting. Retching, also known as dry heaves, involves the stomach and esophageal motions of vomiting without the evacuation of vomitus. Understanding the neurophysiological systems that regulate nausea and vomiting (N&V) has advanced. The central nervous system regulates or mediates both, but through different ways. The autonomic nervous system is the mechanism that causes nausea.

A complicated response that includes the convergence of afferent input is stimulated during vomiting. Neurotransmitters in the chemoreceptor trigger zone, the vomiting center (said to be situated in the nucleus tractus solitarius), and enterochromaffin cells in the gastrointestinal tract emit efferent impulses. These neurotransmitters include serotonin, substance P, and dopamine. These signals are sent to the respiratory center, salivation center, and abdominal muscles. The relative importance of these several routes, which result in N&V symptoms, is complicated. It is proposed to explain agents' varying emetogenicity (intrinsic emetogenicity and mitigating variables [i.e., dose, administration method, and exposure length]) and emetogenic profile (i.e., time to onset, intensity, and duration of symptoms).

Market Dynamics

Chemotherapy-induced nausea and vomiting (CINV) drugs are given to patients who undergo chemotherapy treatment to prevent nausea and vomiting. An increase in the number of patients undergoing chemotherapy is expected to drive the market growth over the forecast period. For instance, according to the data provided by the Centers for Disease Control and Prevention, in November 2022, more than 1 million cancer patients receive chemotherapy or radiation in an outpatient oncology clinic in the U.S. each year.

Key features of the study:

This report provides an in-depth analysis of the global cancer chemotherapy associated nausea and vomiting therapeutics market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cancer chemotherapy associated nausea and vomiting therapeutics market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Eisai Co., Ltd., Pharmanovia, Novartis AG, Merck & Co., Inc., Helsinn Healthcare SA, Dr. Reddy's Laboratories Ltd., Validus Pharmaceuticals LLC, LGM Pharma, Astellas Pharma Inc., AdvaCare Pharma, Norgine, PV Pharma, Fresenius Kabi, Lupin, Hetero Healthcare Limited., Sino Biopharmaceutical Limited, Glenmark Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd, OPKO Health, Inc., Weefsel Pharma, Pfizer Inc., Rosemont Pharmaceuticals Ltd., Starton Therapeutics.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global cancer chemotherapy associated nausea and vomiting therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer chemotherapy associated nausea and vomiting therapeutics market

Detailed Segmentation:

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Type:
- Acute CINV
- Delayed CINV
- Anticipatory nausea and emesis
- Breakthrough CINV/Refractory CINV
Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Drug Class:
- Dopamine Receptor Antagonists
- Metoclopramide
- Chlorpromazine
- Prochlorperazine
- Haloperidol
- Droperidol
- Others
- Serotonin (5-HT3) receptor Antagonists
- Ondansetron
- Granisetron
- Palonosetron
- Dolasetron
- Others
- Substance P/NK-1 Antagonists
- Aprepitant
- Fosaprepitant
- Netupitant
- Others
- Corticosteroids
- Dexamethasone
- Methylprednisolone
- Others
Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Route of Administration:
- Oral
- Parenteral
- Transdermal Patch
Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
- Eisai Co., Ltd.
- Pharmanovia
- Novartis AG
- Merck & Co., Inc.
- Helsinn Healthcare SA
- Reddy's Laboratories Ltd.
- Validus Pharmaceuticals LLC
- LGM Pharma
- Astellas Pharma Inc.
- AdvaCare Pharma
- Norgine
- PV Pharma
- Fresenius Kabi
- Lupin
- Hetero Healthcare Limited.
- Sino Biopharmaceutical Limited
- Glenmark Pharmaceuticals Ltd.
- Otsuka Pharmaceutical Co., Ltd
- OPKO Health, Inc.
- Weefsel Pharma
- Pfizer Inc.
- Rosemont Pharmaceuticals Ltd.
- Starton Therapeutics.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Key Developments
PEST Analysis
PORTER's Analysis
Regulatory Scenario
Merger, Collaboration and Acquisition Scenario
Product Launches/Approvals
Epidemiology

4. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market- COVID-19 Impact Analysis

Economic Impact
Overall Impact on Healthcare Sector
COVID-19 Epidemiology

5. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Type, 2020 - 2032, (US$ Million)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Acute CINV
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Delayed CINV
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Anticipatory nausea and emesis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Breakthrough CINV/Refractory CINV
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

6. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Drug Class, 2020 - 2032, (US$ Million)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Dopamine Receptor Antagonists
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Metoclopramide
Chlorpromazine
Prochlorperazine
Haloperidol
Droperidol
Others
Serotonin (5-HT3) receptor Antagonists
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Ondansetron
Granisetron
Palonosetron
Dolasetron
Others
Substance P/NK-1 Antagonists
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Aprepitant
Fosaprepitant
Netupitant
Others
Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Dexamethasone
Methylprednisolone
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

7. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Route of Administration, 2020 - 2032, (US$ Million)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Transdermal Patch
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

8. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Distribution Channel, 2020 - 2032, (US$ Million)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

9. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Region, 2020 - 2032, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
  - UK
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
  - North Africa
  - Central Africa
  - South Africa

10. Competitive Landscape

Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pharmanovia
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis AG
- Company Highlight
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Merck & Co., Inc.
- Company Highlight
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Helsinn Healthcare SA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Validus Pharmaceuticals LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
LGM Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AdvaCare Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Norgine
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
PV Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Fresenius Kabi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Lupin
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Hetero Healthcare Limited.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sino Biopharmaceutical Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Glenmark Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Otsuka Pharmaceutical Co., Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
OPKO Health, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Weefsel Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Rosemont Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Starton Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies

11. Section

Research Methodology
About Us